Knowledge Graph
Graph explorer
Search resolved entities, walk their edges, and read the sentence behind every one.
Entities25 of 207,987
- large language modeltechnology1,048 mentions
- robotic manipulationmarket834 mentions
- artificial intelligencetechnology739 mentions
- reinforcement learningtechnology492 mentions
- density-functional theorytechnology386 mentions
- Transformertechnology372 mentions
- vision-language-action modeltechnology355 mentions
- agentic AItechnology353 mentions
- Vision-Language Modeltechnology321 mentions
- U.S. Food and Drug Administrationorganization320 mentions
- Microsoftorganization291 mentions
- Googleorganization276 mentions
- NVIDIAorganization264 mentions
- Model Context Protocoltechnology232 mentions
- machine learningtechnology204 mentions
- MarketsandMarketsorganization199 mentions
- Claudeproduct192 mentions
- AI agenttechnology188 mentions
- ChatGPTproduct178 mentions
- Anthropicorganization177 mentions
- integrated sensing and communicationtechnology176 mentions
- Amazon Web Services, Inc.organization174 mentions
- OpenAIorganization172 mentions
- diffusion modeltechnology170 mentions
- IBMorganization163 mentions
Entity
APVO451
product5 mentionslast seen Nov 12, 2026
Lead trispecific candidate being optimized for manufacturing and entering IND enabling studies.
Relationships 6
- Aptevo Therapeutics Inc.developsAPVO45199% confidence5 sources
- APVO451applies tosolid tumor immunotherapy92% confidence1 source
- APVO451applies tocancer treatment90% confidence1 source
- APVO451applies tosolid tumor oncology87% confidence1 source
- APVO451depends onADAPTIR-FLEX85% confidence1 source
- APVO451depends onCD40 activation80% confidence1 source
Relationship
Aptevo Therapeutics Inc.developsAPVO451
99% confidence5 supporting mentions
Either name opens that entity’s relationships.
Sources 5
- filingSEC EDGARNov 12, 2026Aptevo Therapeutics Inc. 8-K: Item 1.01: Entry into a Material Definitive Agreement; Item 3.02: Unregistered Sales of Equity Securities; Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
advancing APVO451, a targeted trispecific immunotherapy candidate
- filingSEC EDGARNov 9, 2026Aptevo Therapeutics Inc. 8-K: Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
advancing APVO451, a targeted trispecific immunotherapy candidate for solid tumors
- filingSEC EDGARNov 5, 2026Aptevo Therapeutics Inc. 8-K: Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
This work includes advancing APVO451, a targeted trispecific immunotherapy candidate for solid tumors
- filingSEC EDGAROct 26, 2026Aptevo Therapeutics Inc. 8-K: Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
This work includes advancing APVO451, a targeted trispecific immunotherapy candidate for solid tumors
- filingSEC EDGARSep 24, 2026Aptevo Therapeutics Inc. 8-K: Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
Aptevo expects to enter Investigational New Drug ("IND") enabling studies for the lead candidate, APVO451